Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.
Pemvidutide may significantly reduce liver fat and improve metabolic parameters in adults with MASH, but further long-term studies are needed to confirm these findings.
Where it sits
this study against the rest of the pemvidutide corpusSummary and findings
This meta-analysis evaluated the efficacy and safety of pemvidutide in adults with metabolic dysfunction-associated steatohepatitis (MASH) compared to placebo. At 12 weeks, pemvidutide significantly reduced liver fat content, body weight, and CAP score. Safety profiles were comparable to placebo, with increased reports of mild-to-moderate nausea.
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) contributes substantially to liver and cardiometabolic disease. Pemvidutide, a dual GLP-1/glucagon receptor agonist, may provide combined hepatic and systemic benefits. We conducted a meta-analysis of randomized controlled trials comparing pemvidutide versus placebo in adults with MASLD/MASH. Data were pooled using random-effects models to estimate mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs). At 12 weeks, pemvidutide significantly reduced liver fat content (MD - 52.90, 95% CI - 71.60 to - 34.20, P < 0.00001), CAP score (MD - 38.30, 95% CI - 70.69 to - 5.91, P = 0.02), body weight (MD - 3.50, 95% CI - 5.00 to - 2.00, P < 0.00001), and blood pressure. At 24 weeks, improvements were seen in ALT (MD - 18.09, 95% CI - 30.12 to - 6.06, P = 0.003), AST (MD - 13.02, 95% CI - 21.84 to - 4.20, P = 0.004), LFC (MD - 45.51, 95% CI - 52.70 to - 38.33, P < 0.00001), and ELF score (MD - 0.44, 95% CI - 0.77 to - 0.11, P = 0.01). Safety was comparable to placebo except for higher mild-to-moderate nausea (P > 0.05). Pemvidutide significantly improves hepatic and metabolic parameters in MASLD/MASH with acceptable tolerability. Larger, longer trials are warranted to confirm antifibrotic efficacy.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.